CCL5 and neoplasm: This study reveals that KMT5C activates DNA damage repair to inhibit STING‐IRF3 pathway, downstream type I IFN signaling and CCL5 secretion, leading to the downregulation of CD8+ T cell infiltration and function in NSCLC, ultimately facilitating tumor progression.